JPH0150449B2 - - Google Patents
Info
- Publication number
- JPH0150449B2 JPH0150449B2 JP58025447A JP2544783A JPH0150449B2 JP H0150449 B2 JPH0150449 B2 JP H0150449B2 JP 58025447 A JP58025447 A JP 58025447A JP 2544783 A JP2544783 A JP 2544783A JP H0150449 B2 JPH0150449 B2 JP H0150449B2
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- hydrophobic
- solution
- component
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 74
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 54
- 239000002502 liposome Substances 0.000 claims abstract description 41
- 239000002904 solvent Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 28
- 239000012530 fluid Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 150000002632 lipids Chemical class 0.000 claims description 79
- 239000012736 aqueous medium Substances 0.000 claims description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000005507 spraying Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- -1 aliphatic fatty acids Chemical class 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 238000005538 encapsulation Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 229920001184 polypeptide Chemical class 0.000 claims description 7
- 108090000765 processed proteins & peptides Chemical class 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 239000000284 extract Chemical class 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 4
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940093541 dicetylphosphate Drugs 0.000 claims description 4
- CAHGCLMLTWQZNJ-BQNIITSRSA-N lanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@]21C CAHGCLMLTWQZNJ-BQNIITSRSA-N 0.000 claims description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- 150000003432 sterols Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 4
- 241000206761 Bacillariophyta Species 0.000 claims description 3
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 3
- NLDBCFRIELDMRO-UHFFFAOYSA-N Stigmasterin Natural products CCCC(CC)C=CC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C NLDBCFRIELDMRO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 3
- KTFZDGGBFILTSA-UHFFFAOYSA-N beta-Sitosterin Natural products CCC(CC)CCC(C)C1CCC2C1CCC3C2CC=C4CC(O)CCC34C KTFZDGGBFILTSA-UHFFFAOYSA-N 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229950005143 sitosterol Drugs 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- ATFFFUXLAJBBDE-FQEVSTJZSA-N N-Stearoyl glutamic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O ATFFFUXLAJBBDE-FQEVSTJZSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229930183167 cerebroside Natural products 0.000 claims description 2
- 229940107161 cholesterol Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 230000001766 physiological effect Effects 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000011782 vitamin Chemical class 0.000 claims description 2
- 229930003231 vitamin Chemical class 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- 235000002961 Aloe barbadensis Nutrition 0.000 claims 1
- 244000186892 Aloe vera Species 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 238000002679 ablation Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 238000003801 milling Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- RQIDQEBURXNDKG-MDZDMXLPSA-N ximenic acid Chemical compound CCCCCCCC\C=C\CCCCCCCCCCCCCCCC(O)=O RQIDQEBURXNDKG-MDZDMXLPSA-N 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 239000002612 dispersion medium Substances 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 4
- 239000012071 phase Substances 0.000 description 64
- 239000000243 solution Substances 0.000 description 44
- 239000000047 product Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000889 atomisation Methods 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000000265 homogenisation Methods 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 6
- 239000000865 liniment Substances 0.000 description 6
- 238000003760 magnetic stirring Methods 0.000 description 6
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940040145 liniment Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940083466 soybean lecithin Drugs 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- QKHBMQWPOUUMQZ-BDQAORGHSA-M sodium;hydron;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC([O-])=O QKHBMQWPOUUMQZ-BDQAORGHSA-M 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8202620A FR2521565B1 (fr) | 1982-02-17 | 1982-02-17 | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR8202620 | 1982-02-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5931707A JPS5931707A (ja) | 1984-02-20 |
| JPH0150449B2 true JPH0150449B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-10-30 |
Family
ID=9271079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58025447A Granted JPS5931707A (ja) | 1982-02-17 | 1983-02-17 | 両親媒性脂質成分を含む微粉状混合物の製造方法 |
Country Status (13)
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2135647A (en) * | 1983-02-15 | 1984-09-05 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
| JPS6058915A (ja) * | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| JPS60155109A (ja) * | 1984-01-23 | 1985-08-15 | Terumo Corp | リポソ−ム製剤 |
| US4744989A (en) * | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4891208A (en) * | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| GB8423436D0 (en) * | 1984-09-17 | 1984-10-24 | Riker Laboratories Inc | Preparation of liposomes |
| US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| JPH0676308B2 (ja) * | 1985-06-18 | 1994-09-28 | ポーラ化成工業株式会社 | 皮膚外用剤 |
| US4683092A (en) * | 1985-07-03 | 1987-07-28 | Damon Biotech, Inc. | Capsule loading technique |
| IL79114A (en) * | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
| US5230899A (en) * | 1985-08-07 | 1993-07-27 | Smithkline Beecham Corporation | Methods and compositions for making liposomes |
| GB8522964D0 (en) * | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| DE3683487D1 (de) * | 1985-10-21 | 1992-02-27 | Liposome Co Inc | In situ-herstellung und verabreichung von liposomen. |
| FR2591105B1 (fr) | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
| JPS62152531A (ja) * | 1985-12-26 | 1987-07-07 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造法 |
| US5023108A (en) * | 1986-01-13 | 1991-06-11 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
| WO1987004070A1 (en) * | 1986-01-13 | 1987-07-16 | Research Corporation | Aqueous dispersions of waxes and lipids for pharmaceutical coating |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| FR2597345B1 (fr) * | 1986-04-22 | 1990-08-03 | Oreal | Composition cosmetique ou pharmaceutique a base d'une dispersion aqueuse de spherules lipidiques. |
| WO1988001864A1 (en) * | 1986-09-18 | 1988-03-24 | Liposome Technology, Inc. | High-concentration liposome processing method |
| US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
| JP2517094B2 (ja) * | 1986-11-28 | 1996-07-24 | ザ リポソーム カンパニー，インコーポレイテッド | リン脂質組成物 |
| JPS63182029A (ja) * | 1987-01-22 | 1988-07-27 | Agency Of Ind Science & Technol | リポソ−ム |
| ATE115403T1 (de) * | 1987-01-27 | 1994-12-15 | Vestar Inc | Aus phospholipiden bestehende darreichungsform für wasserunlösliche wirksubstanzen. |
| CA1321351C (en) * | 1987-02-23 | 1993-08-17 | Helmut Otmar Hauser | Method of dehydrating vesicle preparations for long-term storage |
| US5089181A (en) * | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
| NZ223660A (en) * | 1987-03-05 | 1990-11-27 | Liposome Co Inc | Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| IT1223290B (it) * | 1987-07-27 | 1990-09-19 | Indena Spa | Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche |
| US4963362A (en) * | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| FR2619505B1 (fr) * | 1987-08-20 | 1990-08-31 | Dior Christian Parfums | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la pregnenolone ou un ester de pregnenolone, et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite regeneratrice ou revitalisante, l'incorporant |
| US4950432A (en) * | 1987-10-16 | 1990-08-21 | Board Of Regents, The University Of Texas System | Polyene microlide pre-liposomal powders |
| US5057497A (en) * | 1987-11-10 | 1991-10-15 | Calam & Associates, Inc. | Oral method for the maintenance of healthy gingival tissues using TRF |
| US5290562A (en) * | 1987-11-27 | 1994-03-01 | L V M H Recherche | Compositions and methods employing liposomes including tyrosine or a tyrosine derivative |
| FR2623716B1 (fr) * | 1987-11-27 | 1991-04-05 | Lvmh Rech | Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant de la tyrosine ou un derive de tyrosine et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite pigmentante, l'incorporant |
| US5160669A (en) * | 1988-03-03 | 1992-11-03 | Micro Vesicular Systems, Inc. | Method of making oil filled paucilamellar lipid vesicles |
| US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| US5133965A (en) * | 1988-06-08 | 1992-07-28 | Fountain Pharmaceuticals, Inc. | Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution |
| IL90561A (en) * | 1988-06-08 | 1993-08-18 | Fountain Pharm Inc | Method for making solvent dilution microcarriers |
| FR2633516B1 (fr) * | 1988-06-30 | 1991-03-29 | Clarins | Composition cosmetique pour le traitement des peaux sensibles deshydratees |
| US5096629A (en) * | 1988-08-29 | 1992-03-17 | 501 Nippon Fine Chemical Co., Ltd. | Method for preparing lipid powder for use in preparing liposomes and method for preparing liposomes |
| FR2637182B1 (fr) * | 1988-10-03 | 1992-11-06 | Lvmh Rech | Compositions a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un ecdysteroide, de preference l'ecdysterone, ou l'un de ses derives; et compositions cosmetiques, pharmaceutiques, notamment dermatologiques, de sericulture ou phytosanitaires l'incorporant |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| US5139803A (en) * | 1989-02-09 | 1992-08-18 | Nabisco, Inc. | Method and liposome composition for the stabilization of oxidizable substances |
| US5277914A (en) * | 1989-03-31 | 1994-01-11 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5077057A (en) * | 1989-04-05 | 1991-12-31 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| FR2648462B1 (fr) * | 1989-06-15 | 1994-01-28 | Oreal | Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5246918A (en) * | 1990-07-11 | 1993-09-21 | Unilever Patent Holdings B.V. | Process for preparing perfumed personal products |
| EP0466237B1 (en) * | 1990-07-11 | 1994-03-23 | Quest International B.V. | Stabilized emulsion systems |
| EP0466236B1 (en) * | 1990-07-11 | 1994-08-17 | Quest International B.V. | Perfumed structured emulsions in personal products |
| FR2673840A1 (fr) * | 1991-03-14 | 1992-09-18 | Lvmh Rech | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute. |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| FR2681781A1 (fr) * | 1991-09-30 | 1993-04-02 | Oreal | Composition cosmetique anhydre de maquillage comprenant une phase grasse et procede de traitement cosmetique utilisant cette composition. |
| FR2735658B1 (fr) * | 1995-06-21 | 1997-09-12 | Capsulis | Encapsulation de composes a usage alimentaire par des tensioactifs |
| CA2087691A1 (en) * | 1992-01-23 | 1993-07-24 | Peter Critchley | Cosmetic compositon |
| GB9208339D0 (en) * | 1992-04-15 | 1992-06-03 | Unilever Plc | Treatment composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| FR2695035A1 (fr) * | 1992-08-25 | 1994-03-04 | Lvmh Rech Gie | Utilisation d'un ecdystéroïde pour la préparation de compositions cosmétiques ou dermatologiques destinées notamment à renforcer la fonction protectrice de la peau, et compositions ainsi obtenues. |
| WO1994012155A1 (en) * | 1992-12-02 | 1994-06-09 | Vestar, Inc. | Antibiotic formulation and process |
| US5958449A (en) | 1992-12-02 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for bacterial infections |
| FR2699081B1 (fr) * | 1992-12-11 | 1995-04-07 | Lvmh Rech | Utilisation d'un extrait de Simaba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue. |
| FR2699080B1 (fr) | 1992-12-11 | 1995-04-07 | Lvmh Rech | Utilisation d'un extrait de Simarouba pour l'atténuation des taches pigmentaires cutanées ou pour renforcer la fonction protectrice de la peau, ou pour la préparation d'un milieu de culture de cellules de peau, et composition ainsi obtenue. |
| US5759571A (en) * | 1993-05-11 | 1998-06-02 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for drug resistant infections |
| US5554382A (en) * | 1993-05-28 | 1996-09-10 | Aphios Corporation | Methods and apparatus for making liposomes |
| JPH08512056A (ja) * | 1993-06-30 | 1996-12-17 | ジェネンテク・インコーポレイテッド | リポソームの製造法 |
| DE4430592A1 (de) * | 1994-08-20 | 1996-02-22 | Max Delbrueck Centrum | Liposomale Zubereitung, ihre Herstellung und ihre Verwendung |
| US5702722A (en) * | 1994-09-30 | 1997-12-30 | Bracco Research S.A. | Liposomes with enhanced entrapment capacity, method and use |
| CH689139A5 (de) * | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US7094766B1 (en) | 1995-06-06 | 2006-08-22 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US20030032610A1 (en) * | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| US6147056A (en) * | 1995-06-06 | 2000-11-14 | Trustees Of Boston University | Use of locally applied DNA fragments |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| IN187860B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1997-08-27 | 2002-07-06 | Revlon Consumer Prod Corp | |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US5932562A (en) * | 1998-05-26 | 1999-08-03 | Washington University | Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same |
| WO2000021490A1 (de) * | 1998-10-14 | 2000-04-20 | Cognis Deutschland Gmbh | Verwendung von nanoskaligen sterolen und sterolestern |
| FR2787322B1 (fr) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
| US6080211A (en) * | 1999-02-19 | 2000-06-27 | Igen, Inc. | Lipid vesicle-based fuel additives and liquid energy sources containing same |
| CA2376818A1 (en) * | 1999-06-25 | 2001-01-04 | Cognis Deutschland Gmbh & Co. Kg | Use of nanoscale sterols and sterol esters |
| EP1274410A2 (en) * | 2000-03-31 | 2003-01-15 | Trustees Of Boston University | Use of locally applied dna fragments |
| US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
| EP1534213B1 (en) * | 2002-03-13 | 2013-04-24 | Sköld, Thomas | Water-based delivery systems |
| US20050129722A1 (en) * | 2002-03-13 | 2005-06-16 | Collagenex Pharmaceuticals, Inc. | Water-based delivery systems |
| US20060093661A1 (en) * | 2002-05-07 | 2006-05-04 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| US20030212046A1 (en) * | 2002-05-07 | 2003-11-13 | Kapac, Llc | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| US7306819B2 (en) * | 2002-06-12 | 2007-12-11 | The Coca-Cola Company | Beverages containing plant sterols |
| RU2329734C2 (ru) * | 2002-06-12 | 2008-07-27 | Дзе Кока-Кола Компани | Способ получения дисперсии, напиток и композиция |
| US20060269924A1 (en) * | 2003-04-11 | 2006-11-30 | Trustees Of Boston University | Modulation of telomere-initiated cell signaling |
| US20050153948A1 (en) * | 2003-11-20 | 2005-07-14 | Zomanex, Llc | Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| EP2434009A1 (en) * | 2004-05-19 | 2012-03-28 | Trustees of Boston University | Modulation of WRN-mediated telomere-initiated cell signaling |
| PT1835922E (pt) * | 2004-12-22 | 2009-07-08 | Merck Serono Sa | Tratamento combinado para esclerose múltipla |
| ES2275443B1 (es) | 2005-11-30 | 2008-06-01 | Italfarmaco, S.A. | Procedimiento de preparacion de liposomas. |
| JP2007261984A (ja) * | 2006-03-28 | 2007-10-11 | Konica Minolta Medical & Graphic Inc | 脂肪酸エステルを有するリポソ−ムおよびその製剤 |
| US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| EP2752423A3 (en) | 2006-09-18 | 2015-02-18 | Compugen Ltd. | GPCR ligands and method of using same |
| US20080124387A1 (en) | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| GB0623838D0 (en) | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| US20080207711A1 (en) * | 2007-02-28 | 2008-08-28 | Rong Li | Method for treating an ID2-related disorder |
| US8492329B2 (en) | 2007-07-12 | 2013-07-23 | Compugen Ltd. | Bioactive peptides and methods of using same |
| US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| UA96076C2 (en) | 2007-10-16 | 2011-09-26 | Репрос Терапьютикс Инк. | Use of trans-clomiphene |
| US8101606B2 (en) * | 2007-11-12 | 2012-01-24 | Washington University | Neurofibromin pathway modulators |
| EP3561494B1 (en) | 2007-12-06 | 2022-03-02 | Genalyte, Inc. | METHOD FOR IDENTIFYING A SEQUENCE OF NUCLEOTIDES IN AN UNKNOWN SPECIES OF NUCLEIC ACID 
AND DEVICE FOR CARRYING OUT THE METHOD |
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| ES2939310T3 (es) | 2008-10-27 | 2023-04-20 | Genalyte Inc | Biosensores basados en sondeo y detección ópticos |
| CA2781527C (en) * | 2009-09-23 | 2017-10-24 | Indu Javeri | Methods for the preparation of liposomes |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| CN102906103A (zh) | 2010-03-22 | 2013-01-30 | 利普生物药剂公司 | 用于抗孕酮的非毒性递送的组合物和方法 |
| JP6043278B2 (ja) | 2010-04-09 | 2016-12-14 | パシラ ファーマシューティカルズ インコーポレーテッド | 多小胞リポソームを作製するための方法、大直径合成膜小胞を調製するための方法、および蒸発装置 |
| CA2816995C (en) | 2010-11-05 | 2019-12-31 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, a body corporate and politic | Optical analyte detection systems and methods of use |
| UA113283C2 (xx) | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2672958A1 (en) | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| US20130261010A1 (en) | 2012-03-12 | 2013-10-03 | The Board Of Trustees Of The University Of Illinois | Optical analyte detection systems with magnetic enhancement and methods of use |
| SG11201407397WA (en) | 2012-05-31 | 2014-12-30 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
| CA2888377C (en) | 2012-11-02 | 2021-02-02 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| TR201907471T4 (tr) | 2014-08-28 | 2019-06-21 | Halozyme Inc | Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi. |
| US10406088B2 (en) | 2015-01-20 | 2019-09-10 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
| ES2826896T3 (es) | 2015-05-04 | 2021-05-19 | Versantis AG | Método para preparar vesículas con gradiente de pH transmembrana |
| EP3650546A1 (en) | 2015-07-29 | 2020-05-13 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutic oligonucleotides |
| EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| EP3335028A1 (en) | 2015-08-11 | 2018-06-20 | Scintillon Institute for Biomedical and Bioenergy Research | Optical analyses of particles and vesicles |
| ITUA20161994A1 (it) | 2016-03-24 | 2017-09-24 | Azienda Ospedaliera Univ Senese | Uso degli inibitori ddx3 come agenti anti-iperproliferativi |
| JP7019201B2 (ja) | 2016-08-02 | 2022-02-15 | キュリアールエックス インコーポレーテッド | リポソームの調製方法 |
| WO2020023340A1 (en) | 2018-07-23 | 2020-01-30 | Signalrx Pharmaceuticals, Inc. | Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof |
| EP3850100B1 (en) | 2018-09-12 | 2024-11-06 | The Broad Institute, Inc. | Targeting egln1 in cancer |
| EP4050002A1 (en) | 2021-02-26 | 2022-08-31 | First Health Pharmaceuticals B.V. | Anti-proliferative agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL238195A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1959-04-15 | |||
| US3499962A (en) * | 1967-08-24 | 1970-03-10 | Nat Starch Chem Corp | Encapsulation of water insoluble materials |
| CA1047924A (en) * | 1973-10-30 | 1979-02-06 | Kyowa Hakko Kogyo Co. | Powdered emulsion product and method of production |
| FR2315991A1 (fr) * | 1975-06-30 | 1977-01-28 | Oreal | Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes |
| IN147123B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1976-10-19 | 1979-11-17 | Standard Oil Co Ohio | |
| US4235792A (en) * | 1977-04-14 | 1980-11-25 | The Governing Council Of The University Of Toronto | Immunological materials |
| CH621479A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| IT1110989B (it) * | 1979-01-19 | 1986-01-13 | Erba Farmitalia | Forme farmaceutiche costitutite da liposomi e procedimenti relativi |
| FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
| GB1575344A (en) * | 1978-03-03 | 1980-09-17 | Ici Ltd | Method for the manufacture of liposome composition |
| HU184141B (en) * | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
-
1982
- 1982-02-17 FR FR8202620A patent/FR2521565B1/fr not_active Expired
-
1983
- 1983-02-07 CA CA000421067A patent/CA1208133A/en not_active Expired
- 1983-02-09 AT AT83400281T patent/ATE20574T1/de active
- 1983-02-09 DE DE198383400281T patent/DE87993T1/de active Pending
- 1983-02-09 DE DE8383400281T patent/DE3364299D1/de not_active Expired
- 1983-02-09 EP EP83400281A patent/EP0087993B2/fr not_active Expired - Lifetime
- 1983-02-10 US US06/465,598 patent/US4508703A/en not_active Expired - Lifetime
- 1983-02-15 GR GR70504A patent/GR77128B/el unknown
- 1983-02-16 DK DK67783A patent/DK67783A/da not_active Application Discontinuation
- 1983-02-17 ES ES519878A patent/ES519878A0/es active Granted
- 1983-02-17 IL IL67939A patent/IL67939A0/xx unknown
- 1983-02-17 JP JP58025447A patent/JPS5931707A/ja active Granted
-
1987
- 1987-06-29 SG SG558/87A patent/SG55887G/en unknown
- 1987-11-19 HK HK852/87A patent/HK85287A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5931707A (ja) | 1984-02-20 |
| EP0087993B2 (fr) | 1990-01-03 |
| HK85287A (en) | 1987-11-27 |
| EP0087993B1 (fr) | 1986-07-02 |
| US4508703A (en) | 1985-04-02 |
| FR2521565A1 (fr) | 1983-08-19 |
| ES8404690A1 (es) | 1984-05-01 |
| DK67783D0 (da) | 1983-02-16 |
| ATE20574T1 (de) | 1986-07-15 |
| IL67939A0 (en) | 1983-06-15 |
| EP0087993A1 (fr) | 1983-09-07 |
| DE87993T1 (de) | 1984-02-16 |
| ES519878A0 (es) | 1984-05-01 |
| CA1208133A (en) | 1986-07-22 |
| GR77128B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-09-07 |
| FR2521565B1 (fr) | 1985-07-05 |
| SG55887G (en) | 1987-11-13 |
| DK67783A (da) | 1983-08-18 |
| DE3364299D1 (en) | 1986-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0150449B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3713493C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP4203394B2 (ja) | 高濃度のトリテルペノイドを含有する微小化リポソーム及びその製造方法 | |
| EP0616799B1 (en) | Cosmetic delivery system for salicylic acid and process for preparation of same | |
| JPH0549334B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| KR100810164B1 (ko) | 이데베논 나노캡슐을 함유하는 주름개선 화장료 조성물 및이의 제조방법 | |
| KR100823345B1 (ko) | 코엔자임 큐텐을 포함하는 나노크기의 리포좀 에멀젼을 담지한 실리카 및 그의 제조방법 | |
| JPS6156016B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS61178909A (ja) | ニオソ−ムおよび少くとも一種の水溶性ポリアミドを含有する化粧品または医薬品用組成物およびその製造方法 | |
| KR100654841B1 (ko) | 피부유사구조 및 조성을 갖고 생리활성물질의 경피흡수를촉진하는 지질 용해부 조성물 및 이를 이용한 나노입자화장료의 제조방법 | |
| KR100785484B1 (ko) | 고농도의 이데베논을 나노캡슐화한 기제 조성물, 이의제조방법 및 이를 함유한 화장료 | |
| JP2023160936A (ja) | 難溶性成分安定化用組成物及びそれを含む化粧料組成物 | |
| JP2009120584A (ja) | 連続水相と分散脂肪相とを含むエマルジョンの形態の化粧品組成物、及びその調製方法 | |
| JPH0547258B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| HUT77012A (hu) | Kaolintartalmú kozmetikai készítmény | |
| CN106619149A (zh) | 一种包覆烟酰胺的多囊泡脂质体的制备方法 | |
| CN114366679A (zh) | 一种含有有机酸微粒的脂质体及其制备方法 | |
| CN115702868A (zh) | 包含难溶性成分得到稳定化的纳米囊泡的水包油型化妆料组合物 | |
| KR101507884B1 (ko) | 온도감응성 고분자 지질을 이용하여 친수성 활성물질을 함유한 나노캡슐 농축조성물, 그의 제조방법 및 그를 함유한 화장료 조성물 | |
| CN106726643A (zh) | 一种包覆水溶性光甘草定的多囊泡脂质体及其制备方法 | |
| KR20200070091A (ko) | 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법 | |
| JPH09510432A (ja) | アボカド油不鹸化物を含む脂質小胞 | |
| KR100778903B1 (ko) | 과량의 친수성 생리활성물질을 함유한 나노 농축 캡슐조성물, 이의 제조방법 및 이를 함유한 화장료 조성물 | |
| JP3897940B2 (ja) | 脂質複合体及びこれを含有する外用組成物 | |
| JPH0567605B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |